What Is ATX-304?
ATX-304 is a small-molecule direct pan-AMPK (AMP-activated protein kinase) activator developed as an oral exercise-mimetic and metabolic research compound. Unlike indirect activators — metformin raises the AMP:ATP ratio by inhibiting mitochondrial complex I; AICAR mimics AMP — ATX-304 binds directly to the allosteric drug and metabolite (ADaM) site on AMPK, activating the enzyme without requiring the cell to be in an energy-deficient state. That directness is both its principal advantage and its main trade-off.
ATX-304 has completed a Phase 1 human trial, establishing initial tolerability and pharmacodynamic activity in metabolic indications. No controlled efficacy results in humans have been published. The compound sits between "clinically validated" and "theoretical": the mechanism is well understood, early human safety work is done, and the efficacy trial has not yet been run.
Mechanism of Action
AMPK is the cell's master energy sensor. When ATP is depleted and AMP accumulates — during exercise, caloric restriction, or mitochondrial stress — AMPK activates and orchestrates a coordinated metabolic shift:
- Fat oxidation: AMPK phosphorylates and inactivates ACC (acetyl-CoA carboxylase), reducing malonyl-CoA and removing the brake on CPT-1, which gates fatty acid entry into the mitochondria for beta-oxidation.
- Glucose uptake: AMPK drives GLUT4 translocation to the cell surface, improving insulin-independent glucose uptake in skeletal muscle — the same mechanism responsible for exercise-induced glucose disposal.
- mTOR suppression: AMPK phosphorylates TSC2 and Raptor, suppressing mTORC1. This is the central tension: AMPK and mTOR are functionally antagonistic, and sustained AMPK activation blunts the protein synthesis signal.
- Mitochondrial biogenesis: AMPK activates PGC-1alpha, the master regulator of mitochondrial biogenesis, improving long-term oxidative capacity.
- Autophagy: Via ULK1 phosphorylation, AMPK stimulates cellular clearance of damaged organelles and misfolded proteins.
Because ATX-304 binds the ADaM site directly, AMPK activation occurs whether or not the cell is actually energy-depleted — unconditional firing is the key difference from exercise-induced AMPK activation, which is self-limiting and context-dependent.
Quick Reference
Member reference tables summarize the compound's research parameters.
Research Indications
Research Protocols
As reported in cited literature and research-community logs (see Research Citations below), not a personal dosing recommendation.
This member section describes parameters reported in the research literature.
Peptide Interactions
This member section summarizes reported compound interactions and evidence limitations.
Reported Research Time Points
This member section summarizes reported research time points.
Safety Notes
Included for harm-reduction awareness only, in the event this compound is encountered outside its labeled research use. Inclusion here does not imply RUO Codes endorses, recommends, or instructs human use.
This member section discusses research safety considerations and uncertainties.
Quality Indicators
Research Citations
- Myers RW, et al. "Systemic pan-AMPK activator MK-8722 improves glucose homeostasis but induces cardiac hypertrophy." Science. 2017;357(6350):507–511. Proof-of-concept for direct AMPK activation in glucose homeostasis and class-level cardiac safety signal.
- Steinberg GR, Hardie DG. "New insights into activation and function of the AMPK." Nature Reviews Molecular Cell Biology. 2023;24(4):255–272. Comprehensive review of AMPK structure, ADaM-site pharmacology, and downstream biology relevant to ATX-304's mechanism.
- Hardie DG. "AMPK — sensing energy while talking to other signaling pathways." Cell Metabolism. 2014;20(6):939–952. Foundational review of AMPK's role in mTOR antagonism, mitochondrial biogenesis, and autophagy.
- Esquejo RM, et al. "Activation of liver AMPK with PF-06409577 corrects NAFLD and lowers cholesterol in rodent and primate preclinical models." EBioMedicine. 2018;31:122–132. Direct ADaM-site AMPK activator preclinical data with a metabolic profile comparable to ATX-304's class.
- ATX-304 Phase 1 clinical trial. ClinicalTrials.gov. Results not yet publicly published in full as of 2026.